Developer docs
API playgroundTry for free, no card

Search company profiles

Bend Bioscience

Full company profile

uuid00091pp

Namestring
Bend Bioscience
Legal namestring
CoreRx, Inc., and Societal CDMO, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Bend Bioscience is a U.S. pharmaceutical contract development and manufacturing organization (CDMO) formed in April 2025 from the unification of CoreRx, Societal CDMO, and Bend Bioscience under a single brand. The company serves innovator pharmaceutical and biotechnology companies developing small molecule drug products, providing integrated Design, Develop, and Manufacture services from pre-clinical through commercial scale. Its core capabilities center on enabling technologies for small molecule oral dosage forms, including spray dried dispersions for bioavailability enhancement, particle engineering for powders for inhalation, modified release formulations (sustained, extended, delayed, pulsatile), multiparticulates (Wurster coating, extrusion-spheronization, MUPS), oral solids, oral liquids with pediatric and geriatric formulation expertise, and topical formulations. Supporting service lines include preformulation and process design, analytical and stability testing, technology transfer, and packaging with serialization.

The company operates three FDA-, EMA-, ANVISA-, and DEA-inspected U.S. facilities totaling over 300,000 ft²: Bend, Oregon (R&D and clinical manufacturing with particle engineering and spray drying center-of-excellence); Gainesville, Georgia (commercial manufacturing center-of-excellence for modified release and multiparticulates, with 45+ years of operating heritage); and Clearwater, Florida (preformulation, oral liquids, and low-volume commercial manufacturing). Commercial capacity includes hundreds of millions of dosage units per year at the Georgia site, with a GEA PSD-4 commercial-scale spray dryer (1,250 kg/h gas flow) coming online in 2026.

Bend Bioscience generates revenue through fee-for-service CDMO contracts spanning preformulation, formulation development, analytical testing, cGMP clinical manufacturing, and long-term commercial supply agreements. The go-to-market is enterprise direct sales targeting biotech and pharma decision-makers, supplemented by active participation in industry events such as CPHI, DCAT Week, Drug Delivery and Formulation Summit, and PODD. Pricing is project-specific and quote-based; no public pricing is disclosed. Recent commercial partnerships include an exclusive U.S. manufacturing agreement with Cingulate Inc. for ADHD treatment CTx-1301 through 2028 and a development agreement with Starton Therapeutics for an oral controlled release dosage form of STAR-LLD (lenalidomide).

Short descriptiontext

Bend Bioscience is a U.S. pharmaceutical CDMO formed in 2025 from the unification of CoreRx, Societal CDMO, and Bend Bioscience, serving innovator pharma and biotech with integrated design, development, and manufacturing of small molecule oral dosage forms across three U.S. facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBend, United States
HQ citystring
Bend
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CDMO services, contract development manufacturing, oral dosage formulation, bioavailability enhancement, small molecule manufacturing
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Development and Manufacturing Services
TypeProfessional Services
Description

Fee-for-service CDMO model providing pharmaceutical development and manufacturing services to biotech and pharma companies. Services span preformulation, formulation development, analytical testing, clinical manufacturing, and commercial manufacturing. Revenue generated through project-based contracts, typically multi-year agreements for product development and supply.

bendbioscience.com
2Commercial Manufacturing Supply
TypeManaged Services
Description

Long-term commercial supply agreements for approved drug products, providing ongoing manufacturing capacity and reliable supply to pharmaceutical clients.

bendbioscience.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Bend Bioscience is a pharmaceutical finished-product CDMO providing integrated contract development and manufacturing services for small molecule drug products across three U.S. facilities. The company offers design, development, and cGMP manufacturing services spanning preformulation, formulation, analytical testing, Phase 1-3 clinical manufacturing, commercial manufacturing, packaging, and technology transfer for oral solids, oral liquids, topicals, and powders for inhalation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Superior on-time, in-full (OTIF) delivery rate for clinical and commercial programs
+1 more record
Product overview1 text field

Bend Bioscience is a U.S.-based pharmaceutical CDMO formed from the unification of CoreRx, Societal CDMO, and Bend Bioscience, offering integrated Design, Develop, and Manufacture services for small molecule drug products from pre-clinical through commercial scale. The company's service portfolio centers on enabling technologies including Oral Bioavailability Enhancement (spray dried dispersions, hot melt extrusion, lipid-based formulations), Modified Release (sustained, extended, delayed, pulsatile delivery), Multiparticulates (drug-loaded pellets with custom release profiles), and Oral Dosage Form Design. Supporting these core capabilities are specialized service offerings: Oral Solids, Oral Liquids, Topicals, and Powders for Inhalation for diverse dosage forms; Develop Services providing CMC development from preformulation through scale-up; cGMP Clinical Manufacturing and Commercial Manufacturing for Phase 1-3 through market supply; Analytical & Stability Services for comprehensive testing; Technology Transfer for production transitions; Packaging Services for integrated primary packaging; and Quality & Compliance ensuring FDA, EMA, ANVISA, and DEA regulatory adherence. The company operates three specialized U.S. facilities in Bend, Oregon (particle engineering, spray drying, early-phase development), Gainesville, Georgia (commercial oral solids, modified release, multiparticulates), and Clearwater, Florida (preformulation, oral liquids, low-volume commercial) providing end-to-end development and manufacturing solutions.

Product and service13 records
1Design Services
CategoryService Offering
Description

Strategic formulation design integrating fundamental science with innovative problem solving. Evaluates API properties and architects solutions for formulation and process to ensure product performance and manufacturability for pharmaceutical and biotech clients.

2Develop Services
CategoryService Offering
Description

Applied science and engineering transforming product design into robust manufacturable products through full CMC development, spanning preformulation, analytical development, feasibility, prototyping, and scale-up for pharmaceutical clients.

3cGMP Clinical Manufacturing
CategoryService Offering
Description

Phase 1-3 clinical supply manufacturing across a wide range of oral solid and liquid dosage forms with phase-appropriate controls, regulatory readiness, and supply continuity planning for pharma and biotech sponsors.

4Commercial Manufacturing
CategoryService Offering
Description

Reliable commercial manufacturing for oral solids and liquids with on-time-in-full (OTIF) performance including tablets, capsules, oral liquids, and GMP packaging with serialization for approved drug products.

5Analytical and Stability Services
CategoryService Offering
Description

Fully-equipped on-premise analytical development, QC, and stability testing including spectroscopy, chromatography, dissolution, and ICH stability condition testing for pharmaceutical development and commercial programs.

6Technology Transfer
CategoryService Offering
Description

Cross-disciplinary, transparent technology transfer services to move finished product production including project management, quality and regulatory strategy, gap analysis, and risk assessment for pharmaceutical clients.

7Packaging Services
CategoryService Offering
Description

On-site oral solid and oral liquid dose packaging integrated with manufacturing, including clinical packaging, commercial bottling, blistering, serialization, and aggregation for pharmaceutical clients.

8Quality and Compliance
CategoryService Offering
Description

Comprehensive quality systems and regulatory compliance with proven track record of FDA, EMA, ANVISA, and DEA inspections and cGMP manufacturing standards for pharmaceutical and biotech clients.

9Oral Bioavailability Enhancement
CategoryCore Capability
Description

Enhances oral absorption for poorly bioavailable molecules using amorphous solid dispersion technology including spray dried dispersions, hot melt extrusion, and lipid-based formulations to enable brick dust and lipophilic APIs for pharmaceutical clients.

10Modified Release
CategoryCore Capability
Description

Controlled release formulation services enabling sustained, extended, delayed, pulsatile, or targeted drug delivery profiles to reduce peak-to-trough fluctuations and improve patient convenience, with 35+ years of experience in oral-controlled-release products.

11Multiparticulates
CategoryCore Capability
Description

Drug-loaded and polymer-coated pellets providing custom release profiles, consistent pharmacokinetics, and flexible dosing options through capsules, sachets, or MUPS tablets for pharmaceutical clients.

12Topicals
CategoryCore Capability
Description

Topical product design and development from benchtop to 500L scale with thermo/thermoreversible gel processing for localized treatment to reduce systemic side effects, serving pharmaceutical clients.

13Powders for Inhalation
CategoryCore Capability
Description

Expert particle engineering for spray-dried powders for inhalation using dry powder inhaler (DPI) formulations with optimized aerodynamic performance and consistent particle attributes for pharmaceutical clients.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-17
Description

Exclusive manufacturing partnership for CTx-1301, a next-generation ADHD treatment. Bend serves as the sole U.S. manufacturer through 2028, contingent on FDA approval. Partnership supports Cingulate's preparation for potential market entry with manufacturing security.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-24
Description

Development agreement for oral controlled release dosage form of STAR-LLD (lenalidomide). Bend provides drug delivery R&D support, manufacturing capabilities, and scale-up for Starton's lead candidate - a proprietary oral sustained release formulation designed to improve tolerability and efficacy of lenalidomide for multiple myeloma and chronic lymphocytic leukemia treatment.

Strategic tierMinorTypeOthers
Description

Workforce development partnership including an apprenticeship program designed to prepare students for careers in pharmaceutical sciences with hands-on training and foundational skills.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeBroad incumbent
Description

Global CDMO offering oral solid dose, sterile, and semi-solid manufacturing services. Comparable in serving biotech and pharma clients with commercial supply needs; broader geographic reach than Bend but similarly focused on small molecule drug product manufacturing.

TypeBroad incumbent
Description

Integrated pharmaceutical services provider offering drug development, manufacturing, packaging, and commercialization services. Comparable in offering integrated CDMO plus packaging services with focus on serving small-to-mid biotech and pharma clients across clinical and commercial stages.

TypeBroad incumbent
Description

One of the largest global pharmaceutical CDMOs offering oral, injectable, and biologic drug product development and commercial manufacturing. Broad incumbent with overlapping oral solid dose and bioavailability capabilities but at much greater scale than Bend, serving the same biotech and pharma client base.

TypeBroad incumbent
Description

Operates one of the largest global pharmaceutical CDMO businesses (formerly Patheon) covering oral solids, sterile, APIs, and biologics. Broad incumbent serving the same pharma/biotech customer base as Bend but with substantially larger scale, broader dosage form capabilities, and global footprint.

TypeEmerging player
Description

Pharmaceutical CDMO using proprietary 3D-printing (ZipDose) technology for oral dosage forms. Bend's CEO Owen Murray was most recently CEO of Aprecia, indicating strategic alignment. Comparable in serving biotech clients with novel oral delivery needs, though differentiated by 3DP technology versus Bend's spray drying/modified release focus.

TypeBroad incumbent
Description

Global CDMO leader with small molecule API and drug product capabilities including oral solids and bioavailability enhancement technologies. Comparable to Bend in offering integrated development-to-commercial services but with global footprint and significantly larger scale. Dan Dobry, Bend's CSO, previously led Lonza commercial development.

TypeDirect peer
Description

Specialty CDMO focused on complex oral formulations including poorly soluble molecules using nanoemulsions, amorphous dispersions, and lipid-based systems. Direct peer to Bend's bioavailability enhancement and modified release capabilities serving biotech clients with challenging molecules.

TypeDirect peer
Description

U.S.-based CDMO offering oral solid and liquid dose development and commercial manufacturing for small molecules. Direct peer to Bend with overlapping capabilities in clinical and commercial oral solid dose manufacturing, serving similar biotech and specialty pharma customers.

TypeDirect peer
Description

CDMO specializing in oral drug product development and clinical manufacturing with integrated formulation and clinical testing capabilities. Direct competitor in small molecule oral solid dose formulation, bioavailability enhancement, and clinical-to-commercial transitions.

TypeDirect peer
Description

Specialty CDMO focused on oral drug delivery technologies including modified release, multiparticulates, and taste-masking. Direct peer to Bend's modified release and multiparticulate capabilities, serving similar biotech and specialty pharma customers with similar enabling technology platforms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bend Bioscience

Pharmaceutical Contract Development and Manufacturing (CDMO)bendbioscience.com

Bend Bioscience is a U.S. pharmaceutical CDMO formed in 2025 from the unification of CoreRx, Societal CDMO, and Bend Bioscience, serving innovator pharma and biotech with integrated design, development, and manufacturing of small molecule oral dosage forms across three U.S. facilities.

What Bend Bioscience does

Bend Bioscience is a U.S. pharmaceutical contract development and manufacturing organization (CDMO) formed in April 2025 from the unification of CoreRx, Societal CDMO, and Bend Bioscience under a single brand. The company serves innovator pharmaceutical and biotechnology companies developing small molecule drug products, providing integrated Design, Develop, and Manufacture services from pre-clinical through commercial scale. Its core capabilities center on enabling technologies for small molecule oral dosage forms, including spray dried dispersions for bioavailability enhancement, particle engineering for powders for inhalation, modified release formulations (sustained, extended, delayed, pulsatile), multiparticulates (Wurster coating, extrusion-spheronization, MUPS), oral solids, oral liquids with pediatric and geriatric formulation expertise, and topical formulations. Supporting service lines include preformulation and process design, analytical and stability testing, technology transfer, and packaging with serialization.

The company operates three FDA-, EMA-, ANVISA-, and DEA-inspected U.S. facilities totaling over 300,000 ft²: Bend, Oregon (R&D and clinical manufacturing with particle engineering and spray drying center-of-excellence); Gainesville, Georgia (commercial manufacturing center-of-excellence for modified release and multiparticulates, with 45+ years of operating heritage); and Clearwater, Florida (preformulation, oral liquids, and low-volume commercial manufacturing). Commercial capacity includes hundreds of millions of dosage units per year at the Georgia site, with a GEA PSD-4 commercial-scale spray dryer (1,250 kg/h gas flow) coming online in 2026.

Bend Bioscience generates revenue through fee-for-service CDMO contracts spanning preformulation, formulation development, analytical testing, cGMP clinical manufacturing, and long-term commercial supply agreements. The go-to-market is enterprise direct sales targeting biotech and pharma decision-makers, supplemented by active participation in industry events such as CPHI, DCAT Week, Drug Delivery and Formulation Summit, and PODD. Pricing is project-specific and quote-based; no public pricing is disclosed. Recent commercial partnerships include an exclusive U.S. manufacturing agreement with Cingulate Inc. for ADHD treatment CTx-1301 through 2028 and a development agreement with Starton Therapeutics for an oral controlled release dosage form of STAR-LLD (lenalidomide).

Bend Bioscience firmographics

Firmographics
Name
Bend Bioscience
Legal name
CoreRx, Inc., and Societal CDMO, Inc.
Website
https://bendbioscience.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
251–500 employees
Short description
Bend Bioscience is a U.S. pharmaceutical CDMO formed in 2025 from the unification of CoreRx, Societal CDMO, and Bend Bioscience, serving innovator pharma and biotech with integrated design, development, and manufacturing of small molecule oral dosage forms across three U.S. facilities.
Ownership category
akta.pro rank

Bend Bioscience industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAJ
Packaging, Labeling & Serialization (Clinical/Commercial) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical CDMO services
  • Contract development manufacturing
  • Oral dosage formulation
  • Bioavailability enhancement
  • Small molecule manufacturing

Where Bend Bioscience is headquartered

Location

Headquarters

HQ city
Bend
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Bend Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Fee-for-service CDMO model providing pharmaceutical development and manufacturing services to biotech and pharma companies. Services span preformulation, formulation development, analytical testing, clinical manufacturing, and commercial manufacturing. Revenue generated through project-based contracts, typically multi-year agreements for product development and supply.
  2. Commercial Manufacturing Supply: Long-term commercial supply agreements for approved drug products, providing ongoing manufacturing capacity and reliable supply to pharmaceutical clients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Bend Bioscience product offering

Product offering

Core offering

Bend Bioscience is a pharmaceutical finished-product CDMO providing integrated contract development and manufacturing services for small molecule drug products across three U.S. facilities. The company offers design, development, and cGMP manufacturing services spanning preformulation, formulation, analytical testing, Phase 1-3 clinical manufacturing, commercial manufacturing, packaging, and technology transfer for oral solids, oral liquids, topicals, and powders for inhalation.

Product overview

Bend Bioscience is a U.S.-based pharmaceutical CDMO formed from the unification of CoreRx, Societal CDMO, and Bend Bioscience, offering integrated Design, Develop, and Manufacture services for small molecule drug products from pre-clinical through commercial scale. The company's service portfolio centers on enabling technologies including Oral Bioavailability Enhancement (spray dried dispersions, hot melt extrusion, lipid-based formulations), Modified Release (sustained, extended, delayed, pulsatile delivery), Multiparticulates (drug-loaded pellets with custom release profiles), and Oral Dosage Form Design. Supporting these core capabilities are specialized service offerings: Oral Solids, Oral Liquids, Topicals, and Powders for Inhalation for diverse dosage forms; Develop Services providing CMC development from preformulation through scale-up; cGMP Clinical Manufacturing and Commercial Manufacturing for Phase 1-3 through market supply; Analytical & Stability Services for comprehensive testing; Technology Transfer for production transitions; Packaging Services for integrated primary packaging; and Quality & Compliance ensuring FDA, EMA, ANVISA, and DEA regulatory adherence. The company operates three specialized U.S. facilities in Bend, Oregon (particle engineering, spray drying, early-phase development), Gainesville, Georgia (commercial oral solids, modified release, multiparticulates), and Clearwater, Florida (preformulation, oral liquids, low-volume commercial) providing end-to-end development and manufacturing solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Design Services Strategic formulation design integrating fundamental science with innovative problem solving. Evaluates API properties and architects solutions for formulation and process to ensure product performance and manufacturability for pharmaceutical and biotech clients.
  • Develop Services Applied science and engineering transforming product design into robust manufacturable products through full CMC development, spanning preformulation, analytical development, feasibility, prototyping, and scale-up for pharmaceutical clients.
  • cGMP Clinical Manufacturing Phase 1-3 clinical supply manufacturing across a wide range of oral solid and liquid dosage forms with phase-appropriate controls, regulatory readiness, and supply continuity planning for pharma and biotech sponsors.
  • Commercial Manufacturing Reliable commercial manufacturing for oral solids and liquids with on-time-in-full (OTIF) performance including tablets, capsules, oral liquids, and GMP packaging with serialization for approved drug products.
  • Analytical and Stability Services Fully-equipped on-premise analytical development, QC, and stability testing including spectroscopy, chromatography, dissolution, and ICH stability condition testing for pharmaceutical development and commercial programs.
  • Technology Transfer Cross-disciplinary, transparent technology transfer services to move finished product production including project management, quality and regulatory strategy, gap analysis, and risk assessment for pharmaceutical clients.
  • Packaging Services On-site oral solid and oral liquid dose packaging integrated with manufacturing, including clinical packaging, commercial bottling, blistering, serialization, and aggregation for pharmaceutical clients.
  • Quality and Compliance Comprehensive quality systems and regulatory compliance with proven track record of FDA, EMA, ANVISA, and DEA inspections and cGMP manufacturing standards for pharmaceutical and biotech clients.
  • Oral Bioavailability Enhancement Enhances oral absorption for poorly bioavailable molecules using amorphous solid dispersion technology including spray dried dispersions, hot melt extrusion, and lipid-based formulations to enable brick dust and lipophilic APIs for pharmaceutical clients.
  • Modified Release Controlled release formulation services enabling sustained, extended, delayed, pulsatile, or targeted drug delivery profiles to reduce peak-to-trough fluctuations and improve patient convenience, with 35+ years of experience in oral-controlled-release products.
  • Multiparticulates Drug-loaded and polymer-coated pellets providing custom release profiles, consistent pharmacokinetics, and flexible dosing options through capsules, sachets, or MUPS tablets for pharmaceutical clients.
  • Topicals Topical product design and development from benchtop to 500L scale with thermo/thermoreversible gel processing for localized treatment to reduce systemic side effects, serving pharmaceutical clients.
  • Powders for Inhalation Expert particle engineering for spray-dried powders for inhalation using dry powder inhaler (DPI) formulations with optimized aerodynamic performance and consistent particle attributes for pharmaceutical clients.

Quantifiable outcome

  • Superior on-time, in-full (OTIF) delivery rate for clinical and commercial programs
  • +1 more outcomes

Companies that use Bend Bioscience

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Bend Bioscience technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Bend Bioscience partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Cingulate Inc.coreStrategic or Co-development Partner · 17 September 2025Exclusive manufacturing partnership for CTx-1301, a next-generation ADHD treatment. Bend serves as the sole U.S. manufacturer through 2028, contingent on FDA approval. Partnership supports Cingulate's preparation for potential market entry with manufacturing security.
  • Starton TherapeuticscoreStrategic or Co-development Partner · 24 June 2025Development agreement for oral controlled release dosage form of STAR-LLD (lenalidomide). Bend provides drug delivery R&D support, manufacturing capabilities, and scale-up for Starton's lead candidate - a proprietary oral sustained release formulation designed to improve tolerability and efficacy of lenalidomide for multiple myeloma and chronic lymphocytic leukemia treatment.
  • Lanier Technical CollegeminorOthersWorkforce development partnership including an apprenticeship program designed to prepare students for careers in pharmaceutical sciences with hands-on training and foundational skills.

Scale indicators8 records

Recent moves11 records

Expansion highlights8 records

Bend Bioscience competitors and assessment

Company assessment

Broad incumbents

  • Recipharm: Global CDMO offering oral solid dose, sterile, and semi-solid manufacturing services. Comparable in serving biotech and pharma clients with commercial supply needs; broader geographic reach than Bend but similarly focused on small molecule drug product manufacturing.
  • PCI Pharma Services: Integrated pharmaceutical services provider offering drug development, manufacturing, packaging, and commercialization services. Comparable in offering integrated CDMO plus packaging services with focus on serving small-to-mid biotech and pharma clients across clinical and commercial stages.
  • Catalent: One of the largest global pharmaceutical CDMOs offering oral, injectable, and biologic drug product development and commercial manufacturing. Broad incumbent with overlapping oral solid dose and bioavailability capabilities but at much greater scale than Bend, serving the same biotech and pharma client base.
  • Thermo Fisher Scientific (Patheon): Operates one of the largest global pharmaceutical CDMO businesses (formerly Patheon) covering oral solids, sterile, APIs, and biologics. Broad incumbent serving the same pharma/biotech customer base as Bend but with substantially larger scale, broader dosage form capabilities, and global footprint.
  • Lonza Pharma & Biotech: Global CDMO leader with small molecule API and drug product capabilities including oral solids and bioavailability enhancement technologies. Comparable to Bend in offering integrated development-to-commercial services but with global footprint and significantly larger scale. Dan Dobry, Bend's CSO, previously led Lonza commercial development.

Emerging players

  • Aprecia Pharmaceuticals: Pharmaceutical CDMO using proprietary 3D-printing (ZipDose) technology for oral dosage forms. Bend's CEO Owen Murray was most recently CEO of Aprecia, indicating strategic alignment. Comparable in serving biotech clients with novel oral delivery needs, though differentiated by 3DP technology versus Bend's spray drying/modified release focus.

Direct peers

  • Ascendia Pharmaceuticals: Specialty CDMO focused on complex oral formulations including poorly soluble molecules using nanoemulsions, amorphous dispersions, and lipid-based systems. Direct peer to Bend's bioavailability enhancement and modified release capabilities serving biotech clients with challenging molecules.
  • Halo Pharma: U.S.-based CDMO offering oral solid and liquid dose development and commercial manufacturing for small molecules. Direct peer to Bend with overlapping capabilities in clinical and commercial oral solid dose manufacturing, serving similar biotech and specialty pharma customers.
  • Quotient Sciences: CDMO specializing in oral drug product development and clinical manufacturing with integrated formulation and clinical testing capabilities. Direct competitor in small molecule oral solid dose formulation, bioavailability enhancement, and clinical-to-commercial transitions.
  • Adare Pharmaceuticals: Specialty CDMO focused on oral drug delivery technologies including modified release, multiparticulates, and taste-masking. Direct peer to Bend's modified release and multiparticulate capabilities, serving similar biotech and specialty pharma customers with similar enabling technology platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Bend Bioscience social profiles

Digital presence

Bend Bioscience compliance and trust

Trust signal

Compliance3 records

Bend Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bend Bioscience leadership team

Management profile

Number of profiles

Profiles7 records

Bend Bioscience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bend Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bend Bioscience

What does Bend Bioscience do?

Bend Bioscience is a pharmaceutical finished-product CDMO providing integrated contract development and manufacturing services for small molecule drug products across three U.S. facilities. The company offers design, development, and cGMP manufacturing services spanning preformulation, formulation, analytical testing, Phase 1-3 clinical manufacturing, commercial manufacturing, packaging, and technology transfer for oral solids, oral liquids, topicals, and powders for inhalation.

Is Bend Bioscience a public or private company?

Bend Bioscience is a private company. It is classified as unknown and is currently operating.

When was Bend Bioscience founded?

Bend Bioscience was founded in 2021. It employs 251 to 500 people.

Where is Bend Bioscience based?

Bend Bioscience is headquartered in Bend, United States, in the North America region.

How does Bend Bioscience make money?

Two revenue lines are on record. Contract Development and Manufacturing Services are the primary driver. The others are commercial Manufacturing Supply.

Who are Bend Bioscience's main competitors?

Broad incumbents on record are Recipharm, PCI Pharma Services, Catalent, Thermo Fisher Scientific (Patheon) and Lonza Pharma & Biotech. Aprecia Pharmaceuticals is listed as an emerging player. Direct peers are Ascendia Pharmaceuticals, Halo Pharma, Quotient Sciences and Adare Pharmaceuticals.

Does Bend Bioscience have an API?

No public API is recorded for Bend Bioscience.

What industry is Bend Bioscience in?

Bend Bioscience's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Bend Bioscience Names Pavlos Pavlidis President And Sandeep Patel CFOBend Bioscience appointed Pavlos Pavlidis as President and Sandeep Patel as CFO. Pavlidis brings over two decades of leadership experience, including roles at Medix Infusion, McKesson, and Biogen, while Patel has over 20 years in investment banking and CFO roles. The appointments aim to strengthen Bend's operations and strategic investments as it expands its small molecule CDMO capabilities.The Pharma LetterBend Bioscience strengthens executive leadership teamBend Bioscience appointed Pavlos Pavlidis as president and Sandeep Patel as chief financial officer. Pavlidis previously served as president and COO at Medix Infusion and held senior roles at McKesson, AppianRx, UnitedHealth Group, and Biogen. The appointments aim to strengthen the company's leadership as it expands capabilities and operations.EIN PresswireU.S. Pharmaceutical Spray Drying CDMO Services Market Set to Boom Rapidly by 2033 | CritiTech, Elise BiopharmaThe U.S. pharmaceutical spray drying CDMO services market is projected to grow from USD 854.2 million in 2026 to USD 1,473.5 million by 2033, a CAGR of 8.1%. Pilot/clinical-scale services lead with a 78.5% share in 2025, while small molecules and APIs account for 42.1% of the product segment.GlobeNewswireFDA Accepts Cingulate’s New Drug Application for CTx-1301The FDA has accepted Cingulate Inc.'s New Drug Application for CTx-1301, a once-daily ADHD treatment candidate using the company's proprietary Precision Timed Release technology, with a PDUFA target action date set for May 31, 2026. The NDA acceptance under the 505(b)(2) regulatory pathway validates the completeness of Cingulate's clinical and CMC data packages following positive Phase 3 trial results demonstrating rapid onset and sustained efficacy throughout the active day in both adult and pediatric patients. Cingulate is advancing commercial readiness through partnerships with Bend Bio Sciences for manufacturing and Indegene for omnichannel commercialization, positioning the company to potentially transition from development-stage to commercial-stage in 2026 pending FDA approval.The Manila TimesCingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD TreatmentCingulate Inc. entered a commercial supply agreement with Bend Bio Sciences to manufacture CTx-1301, its lead ADHD treatment, with Bend as exclusive U.S. commercial manufacturer through 2028. Cingulate submitted its NDA to the FDA on July 31, 2025, and will purchase 100% of U.S. commercial supply from Bend pending approval.Stock TitanCingulate Partners with Bend Bio for ADHD Drug ManufacturingCingulate Inc. entered a commercial supply agreement with Bend Bio Sciences for exclusive U.S. manufacturing of its ADHD drug CTx-1301 through 2028. The company submitted its NDA to the FDA on July 31, 2025, and will purchase 100% of its U.S. commercial supply from Bend.GlobeNewswireCingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD TreatmentCingulate Inc. has entered into an exclusive commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301, its lead ADHD treatment candidate. Under the agreement, Bend Bio Sciences will serve as the exclusive commercial manufacturer of CTx-1301 in the United States through 2028, contingent on FDA approval, with Cingulate committing to purchase 100% of its U.S. commercial supply. The partnership follows Cingulate's NDA submission for CTx-1301 on July 31, 2025, and is positioned as a key step toward potential market entry for the therapy designed to address limitations of current ADHD treatments.BendbioscienceCoreRx, Societal CDMO, and Bend Bioscience Unite Under the Bend Bioscience Brand to Provide World Class CDMO OfferingCoreRx, Societal CDMO, and Bend Bioscience have announced their unification under the Bend Bioscience brand to form a comprehensive contract development and manufacturing organization (CDMO). The merged entity combines CoreRx’s formulation development expertise, Societal CDMO’s manufacturing capabilities, and Bend Bioscience’s research leadership to offer end-to-end drug development services. This strategic move aims to enhance operational efficiencies and accelerate the delivery of therapies to global markets.GlobeNewswireStarton Therapeutics and Bend Bioscience Enter into Development Agreement for Oral Controlled Release Dosage Form of STAR-LLD (lenalidomide)Starton Therapeutics and Bend Bioscience signed a development agreement for an oral controlled-release dosage form of STAR-LLD, a lenalidomide delivery system. Bend will provide drug delivery R&D and manufacturing support, aiming to improve tolerability and patient compliance. The collaboration builds on prior clinical data showing reduced hematologic toxicity.ContractpharmaBend Bioscience’s Expanded Vision for Complex Drug DeliveryBend Bioscience, a CDMO, is expanding its operations in Clearwater, Florida and Gainesville, Georgia, to address complex oral and inhaled drug delivery. The company emphasizes high science and high service, collaborating with big pharma and academic institutions. It aims to help partners translate scientific breakthroughs into real-world therapies.